IP/C/R/TC/WHO/3  
 
26 September 2022  
(22-7211)  Page: 1/16 
Council for Trade -Related Aspects  of 
Intellectual Property Rights  Original: English   
 
TECHNICAL COOPERATION ACTIVITIES: INFORMATION FROM  
OTHER INTERGOVERNMENTAL ORGANIZATIONS  
WORLD HEALTH ORGANIZATION (WHO)  
At its meeting of  6 July  2022, the Council for TRIPS agreed to invite intergovernmental organization 
observers to the Council to update the information on their technical and financial cooperation 
programmes relating to the implementation of the TRIPS Agreement.  
 
The present document reproduces the information which has been received from the World Health  
Organization (WHO)  by means of a communication dated  19 September 2022 . 
 
_______________  
 
1  INTRODUCTION  
1.  This communication summarizes the technical cooperation activities of the WHO in the area of 
public health, innovation and intellectual property that have taken place since the last report in 
October 2021 (document IP/C/R/TC/WHO/2). The overall objective of WHO 's technical cooperation 
is to strengthen the capacity of developing countries in the areas of health innovation, access to 
medicines and ma nagement of intellectual property.  
2.  WHO's technical cooperation is based on its mandate derived from the Global Strategy and Plan 
of Action on Public Health, Innovation and Intellectual Property (GSPA -PHI) as well as relevant 
resolutions and decisions  of the World Health Assembly, including WHA72.8 on 'Improving the 
transparency of markets for medicines, vaccines, and other health products1', WHA73.1 on the 
'COVID -19 response2', WHA74.6 on 'Strengthening local production of medicines and other health 
technologies to improve access3"and WHA75.14 on the extension of the time frame of the "Global 
Strategy and Plan of Action on Public Health, Innovation and Intellectual Property " from 2022 to 
2030.4 
3.  In resolution WHA74.6, the Seventy -fourth World Health Assembly emphasized the need to 
improve access to quality, safe, effective and affordable medicines and other health technologies, 
inter alia, through cooperation with, support to and development of voluntary patent pools and other 
voluntary initiatives, s uch as the WHO COVID -19 Technology Access Pool (C -TAP) and the Medicines 
Patent Pool. WHA74.6, inter alia, requested the WHO Director -General to continue to provide 
technical support, as appropriate, upon request, in collaboration with other competent inte rnational 
organizations, in particular WIPO and WTO, including to policy processes and to countries that intend 
to make use of the provisions contained in the TRIPS Agreement, including the flexibilities affirmed 
by the Doha Declaration on the TRIPS Agreem ent and Public Health in order to promote access to 
pharmaceutical products.5 
4.  WHO, through its headquarters, regional and country offices collaborates closely with relevant 
international organizations on topics related to the interface between public health, innovation, 
 
1 https://apps.who.int/gb/ebwha/pdf_files/WHA72/A72_R8 -en.pdf  
2 https://apps.who.int/gb/ebwha/pdf_files/WHA7 3/A73_R1 -en.pdf  
3 https://apps.who.int/gb/ebwha/pdf_files/WHA74/A74_R6 -en.pdf  
4 https://apps.who.int/gb/ebwha/pdf_files/WHA75/A75_R14 -en.pdf  
5 https://apps.who.int/gb/ebwha/pdf_files/WH A74/A74_R6 -en.pdf  IP/C/R/TC/WHO/3  
 
- 2 - 
 
  intellectual property and trade. WHO has requested full support and collaboration from W orld 
Intellectual Property Organization  (WIPO) , World Trade Organization  (WTO)  and other international 
organizations to ensure efficient and effective implementation of certain prioritized actions of the 
GSPA -PHI overall programme review panel. Activities focus on technical guidance,  transfer of 
technology, local manufacturing, capacity -building and training, and direct technical assistance to 
countries. WHO, WIPO and WTO are also working in close collaboration to respond to the challenges 
posed by the COVID -19 pandemic in relation to  the integrated health, trade and IP policy framework, 
including equitable access to COVID -19 health technologies, such as medicines, vaccines, medical 
devices, and diagnostics.  
2  AN INTEGRATED HEALTH, TRADE AND INTELLECTUAL PROPERTY APPROACH TO 
RESPOND TO T HE COVID -19 PANDEMIC  
5.  On 30 August 2021, WHO, WIPO and WTO launched an update of the information note "Integrated 
health, trade and IP approach to respond to the COVID -19 pandemic ".6 This information note maps 
the challenges posed by the COVID -19 pandemic  in relation to the integrated health, trade and 
intellectual property framework set out in the second edition of the Trilateral Study on "Promoting 
Access to Medical Technologies and Innovation ".7 The update contains developments up until 
30 August 2021, including on the impact of COVID -19 on health systems and responses at the global 
level, policy challenges, meeting the demand for health technologies and medical services, 
international trade, intellectual property aspects, international initiatives to su pport research and 
development and equitable access, regulatory responses, transparency and mapping the way 
forward.  
3  INTENSIFIED COOPERATION IN SUPPORT OF ACCESS TO MEDICAL TECHNOLOGIES 
WORLDWIDE TO TACKLE THE COVID -19 PANDEMIC  
6.  Within the existing Trilater al collaboration framework between WHO, WIPO and WTO, the 
COVID - 19 Technical Assistance Platform was created as a one -stop shop for the three organizations 
to make available their expertise in public health, IP and trade matters in a coordinated and 
systematic manner to help Members address the COVID -19 pandemic.8 The Platform also facilitates 
the provision of tripartite technical assistance on the pathways for accessing vaccines, medicines 
and technologies, including through coordination between members facing similar challenges to 
facilitate collective responses.  
7.  The Directors -General of the WHO, WIPO and WTO agreed to organize practical capacity -building 
workshops at the technical level to enhance the flow of updated information on current developments 
in the pandemic and responses to achieve equitable access to COVID -19 health technologies.9 The 
first in the series of workshops titled "WHO, WIPO, WTO Workshop on Innovation in, and Access to, 
COVID -19 Technologies " was held on 27 September 2021 to discuss technology transfer and 
licensing as specific IP policy options. The workshop, held virtually, conveyed information to enhance 
knowledge and understanding of how IP, know -how and technology transfer work in practice, not 
only vis -à-vis medical tech nologies but also for related products and services. This was aimed at 
strengthening the capacity of policymakers and experts in member governments to address the 
pandemic accordingly.10 
8.  On 1 February 2022, the Directors -General of WHO, WIPO and WTO met in  Geneva to review 
progress made on the initiatives announced in their Joint Statement during their previous meeting 
in June 2021.11 They welcomed the launch of the trilateral technical assistance platform and reviewed 
the series of technical capacity build ing workshops planned, starting with the workshop on 
intellectual property licensing and technology transfer held in September 2021. The 
Directors - General also welcomed the ongoing efforts by their three organizations to make up -to-
date information availa ble, including the series of joint COVID -19 information notes to update the 
Trilateral Study "Promoting Access to Medical Technologies and Innovation ". Finally, the three 
Directors -General confirmed that they would convene a high -level policy symposium in 2022 on the 
 
6 https://www.wto.org/english/news_e/news21_e/trip_22oct21_e.htm  
7 https://w ww.wto.org/english/res_e/booksp_e/who -wipo-wto-2020_e.pdf  
8 https://www.who -wipo-wto-trilateral.org/  
9 https://www.wto.or g/english/news_e/news21_e/igo_23jun21_e.htm  
10 https://www.wipo.int/meetings/en/details.jsp?meeting_id=65948  
11 https://www.wto.org/english/news_e/news22_e/igo_01feb22_e.htm  IP/C/R/TC/WHO/3  
 
- 3 - 
 
  COVID -19 pandemic, taking stock of COVID -19 challenges and focusing on what is needed to recover 
from this health crisis and better prepare for future ones.  
9.  On 28 February 2022, WHO, WIPO and WTO jointly organized a workshop focused on access a nd 
use of information resources for COVID -19 response.12 The purpose of the workshop was to enhance 
understanding of the characteristics, potential uses and limitations of particular information sources 
related to the pandemic. Points raised for future con sideration included the connection of various 
data resources, the importance of coherent information across resources, the utility of expanding 
resources to include data related to other diseases and how to leverage or improve resources to 
prepare for futu re pandemics.  
4  COVID -19 TECHNOLOGY ACCESS POOL (C -TAP)  
10.  Since its creation in May 2020, the WHO COVID -19 Technology Access Pool (C -TAP) has 
prioritized engagement with technology holders to encourage sharing of intellectual property, 
know - how or data to pro mote global equitable access of COVID -19 vaccines, therapeutics, 
diagnostics or other medical devices. In November 2021, under the auspices of C -TAP, the Medicines 
Patent Pool (MPP) signed a worldwide license with the Spanish National Research Council (CSI C) for 
a COVID - 19 serological antibody diagnostic test.13 The diagnostic test effectively checks for the 
presence of anti  SARS -CoV-2 antibodies developed either in response to a COVID -19 infection or to 
a vaccine. This license was the first transparent, g lobal, non -exclusive license for a COVID -19 health 
tool, and the first test license signed by MPP and included in C -TAP. The license will facilitate the 
rapid manufacture and commercialization of CSIC 's COVID -19 serological test worldwide. The 
agreement co vers all related patents and the biological material necessary for manufacture of the 
test. CSIC will provide all know -how to prospective licensees as well as training. The license will be 
royalty -free for low - and middle -income countries and will remain v alid until the date the last patent 
expires.14 The MPP subsequently sublicensed this technology to Biotech Africa to promote access in 
low and middle -income countries.15 Under the sublicense, CSIC will share all proprietary know -how 
and other technical kno wledge relating to its patent rights which may be necessary for Biotech Africa 
to make full use of the patents and biological material.16 
11.  In May 2022, under the auspices of C -TAP, the MPP signed two licensing agreements with the 
United States National Inst itutes of Health (NIH) for the development of 11 innovative therapeutics, 
early-stage vaccines and diagnostic tools for COVID -19.17 This was the second worldwide, non -
exclusive and transparent license for technologies included in C -TAP. The license was gra nted after 
an assessment of the technologies by C -TAP's Technical Advisory Group (TAG).18 
12.  On its second -year anniversary, C -TAP organized a Panel Discussion Webinar to stimulate the 
debate on advancing C -TAP's ability to promote equitable access to COVID -19 health technologies, 
informed by two papers prepared by the C -TAP Secretariat. The first paper reviewed existing 
literature on technology transfer and affordable access in funding agreements in the context o f 
medical products to address pandemic diseases. The review focused on specific contractual terms 
and conditions and associated policies related to the funding of research and development (R&D), 
clinical trials, and the manufacturing of medical products, p articularly those needed to respond to 
international public health crises. The second paper provided in its first section a summary of 
responses by Member States to a WHO C -TAP incentive questionnaire.  
13.  The questionnaire listed a set of measures that could be implemented by Member States to 
encourage technology holders to pool technologies through C -TAP. The second part of the paper 
included a review based on academic papers, conferences, and any other publicly available resource 
that was undertaken by C -TAP Secretariat to complement and facilitate the discussion. Panelists and 
 
12 https://www.wto.org/english/news_e/ne ws22_e/trip_28feb22_e.htm  
13 https://www.who.int/initiatives/covid -19-technology -access -pool/csic -license  
14 https://www.who.int/news/item/23 -11-2021-who-and-mpp-announce -the-first-transparent -global -
non-exclusive -licence -for-a-covid-19-technology  
15 https://cdn.who.int/media/docs/default -source/medicines/c -tap/sublicence -agreement -mpp-biotech -
africa.pdf?sfvrsn=59cc142e_1  
16 https://medicinespatentpool.org/licence -post/elisa -antibody -technology  
17 https: //www.who.int/initiatives/covid -19-technology -access -pool/us -nih-licenses  
18 https://www.who.int/publications/m/item/tag -report -nih-licenses -publication  IP/C/R/TC/WHO/3  
 
- 4 - 
 
  participants were invited to share their views on how to make C -TAP more attractive to technology 
holders based on the findings from the two papers .19 
5  THE MRNA VACCINE TECHNOLOGY TRANS FER HUB  
14.  In June 2021, WHO in partnership with the Coalition for Epidemic Preparedness Innovations 
(CEPI) and Gavi , the Vaccine Alliance,  collaborated with a South African consortium (comprising 
Biovac, Afrigen Biologics and Vaccines, a network of universit ies and the African Centers for Disease 
Control and Prevention) to establish the first COVID -19 mRNA vaccine technology transfer hub 
located in Cape Town, South  Africa.20The creation of the technology transfer hub is a strategy to 
build capacity in low - and middle - income countries to produce mRNA vaccines, thus promoting 
equitable access in under - served regions.21 The technology transfer hub will perform clinical 
development of licensed technology and serve as a training facility for interested manufactur ers 
from low -and middle -income countries. WHO and partners will bring in the production know -how, 
quality control and necessary licenses to a single entity to facilitate a broad and rapid technology 
transfer to multiple recipients.  
15.  On 18 February 2022, WHO  announced the first recipients of technology from the mRNA vaccine 
technology transfer hub to produce mRNA vaccines.22 The first selected countries are Egypt, Kenya, 
Nigeria, Senegal, South Africa and Tunisia. WHO and partners will work with the beneficia ry countries 
to develop a roadmap for necessary training and support so that they can start producing vaccines 
on the African continent. As of August 2022, the list of recipients  has been expanded to include 
Argentina, Brazil, Bangladesh, India, Indonesia,  Pakistan, Serbia, Ukraine and Viet Nam.23 The WHO 
mRNA technology transfer hub is part of a larger effort aimed at empowering low - and 
middle - income countries to produce their own vaccines, medicines and diagnostics to address health 
emergencies and reach universal health coverage.  
16.  On 23 February 2022, WHO led the establishment of a global bio -manufacturing training hub in 
the Republic of Korea to serve all low - and middle -income countries wishing to produce biologicals, 
such as vaccin es, insulin, monoclonal antibodies and cancer treatments.24 The facility located outside 
Seoul, will provide technical and hands -on training on operational and good manufacturing practice 
requirements and is set to complement the trainings delivered by the  mRNA vaccine technology 
transfer hub in South Africa.  
17.  As part of the "Regional Platform to Advance the Manufacturing of COVID -19 Vaccines and other 
Health Technologies in the Americas " initiative led by the Pan American Health Organization in 
collaboratio n with WHO and the Medicines Patent Pool, a group of vaccine manufacturers from Brazil 
and Argentina were the first to receive technology transfer training in mRNA vaccines.25 The training 
was carried out at Afrigen in South Africa. It is aimed at scaling up local manufacturing capacity to 
improve equitable access to essential medicines and health technologies in the Latin American 
region.  
6  ACCESS TO COVID -19 TOOLS ACCELERATOR (ACT -A) 
18.  ACT-A was launched in April 2020 as a collaborative effort to accelerate t he development, 
production and equitable access to COVID -19 tests, treatments, and vaccines. ACT -A is organized 
around three main pillars of work: diagnostics, therapeutics and vaccines (COVAX), with a 
cross- cutting Health Systems and Response Connector ( HSRC) and Access and Allocation 
 
19 https://www.who.int/news -room/events/detail/2022/06/16/default -calendar/webinar --realizing -
equitable -global -access -to-covid-19-health -technologies. -who-c-tap-s-progress --challenges -and-opportunities  
20 https://www.who.int/news/item/21 -06-2021-who-supporting -south -african -consortium -to-establish -
first-covid-mrna-vaccine-technology -transfer -hub 
21 https://www.who.int/initiatives/the -mrna-vaccine -technology -transfer -hub 
22 https://www.who.int/news/item/18 -02-2022-who-announces -first-technology -recipients -of-mrna-
vaccine -hub-with-strong -support -from-african -and-european-partners  
23 https://www.who.int/initiatives/the -mrna-vaccine -technology -transfer -hub/recipi ents-of-mrna-
technology -from-the-who-mrna-technology -transfer -hub 
24 https://www.who.int/news/item/23 -02-2022-moving -forward -on-goal-to-boost -local-pharmaceutical -
production -who-establishes -global -biomanufacturing -training -hub-in-republic -of-korea  
25 https://www.paho.org/en/news/24 -3-2022-latin-american -manufacturers -complete -first-training -
mrna-technology -bid-improve  IP/C/R/TC/WHO/3  
 
- 5 - 
 
  workstream. As of 30 June 2022, COVAX, the vaccines pillar of ACT -A, has delivered more than 
1.6 billion COVID - 19 vaccine doses.26 The Diagnostics pillar has procured more than 175.7 million 
tests and more than USD 767 mill ion worth of personal protective equipment (PPE). The therapeutics 
pillar has procured over USD 578 million worth of medical oxygen supplies and repaired 180 Pressure 
Swing Adsorption (PSA) plants. Other major achievements of ACT -A include funding research  and 
development of new therapeutics, diagnostics and vaccines, as well as supporting the market entry 
of new, affordable rapid tests.27 
19.  In January 2022, WHO partnered with UNICEF and G avi, the Vaccines Alliance,  to create the 
COVID -19 Vaccine Delivery Par tnership to expedite vaccine delivery in 34 countries that were at or 
below 10% full vaccination coverage to progress towards national and global targets.28 This initiative 
prioritizes full vaccination and boosters for high -priority populations such as old er adults, health care 
workers and persons with co -morbidities.  
7  MULTILATERAL LEADERS TASK FORCE ON COVID -19 VACCINES, THERAPEUTICS AND 
DIAGNOSTICS  
20.  The Multilateral Leaders Task Force, co -led by WHO, WTO, the World Bank Group and the 
International Monetary Fund, held a series of meetings between October 2021 and 
December  2021.29 On 9 November 2021, the Task Force held the 2nd High Level Consultations with 
the CEOs of leading COVID -19 vaccine manufacturing companies.30 The objective of the meeting 
was to identify how to ensure more equitable distribution of vaccines and all those participating 
pledged to continue working together to gain greater clarity on donations, vaccine swaps and 
delivery schedules so that distribution of the life -saving vaccines can be more effectively targeted 
towards those countries most in need. At the meeting, all participants agreed on the urgency of 
delivering more vaccine doses to low -income countries, where less than 2.5% of the population has 
been fully vaccinated.  
21.  At its eig hth meeting in March 2022, the Task Force focused on rapid vaccine delivery to where 
they are needed the most and putting those vaccines into arms.31 In its joint statement, the Task 
Force called for sustained investment in geographically diversified manuf acturing capacity and new 
technologies for vaccines, therapeutics, and diagnostics as key for ensuring more equitable, 
affordable, and timely access to tools for developing countries. It also emphasized close coordination 
among all stakeholders as crucial to aligning supply with demand, reducing supply fragmentation, 
and deploying vaccines in the most effective way.  
22.  The Task Force, along with ACT -A, rolled out the "COVID -19 Global Tracker " – a new tool 
designed to track progress towards ending the COVID -19 pandemic along key dimensions, including 
access and deployment of vaccines, treatments, tests, PPE, other tools, and the financing needed to 
end the pandemic.32 
_______________  
 
 
 
 
26 https://www.act -a.org/impact  
27 https://www.act -a.org/impact  
28 https://www.act -a.org/vaccines -covax  
29 https://www.covid19taskforce.com/en/programs/task -force-on-covid-19-vaccines  
30 https:// www.wto.org/english/news_e/news21_e/igo_09nov21_e.htm  
31 https:// www.worldbank.org/en/news/statement/2022/03/07/eighth -meeting -of-the-multilateral -
leaders -task-force-on-covid-19-1-march -2022-third-consultation -with-the-ceos-of-leadi 
32 https://www.covid19globaltracker. org  
  IP/C/R/TC/WHO/3  
 
- 6 - ANNEX1 
Name of programme or project  WHO -WIPO -WTO COVID -19 Technical Assistance Platform  
Date and end date  11 April 2022  
Beneficiary Member(s) or observer(s)  Afghanistan; Albania; Algeria; Andorra; Angola; Antigua and Barbuda; Argentina; 
Armenia; Australia; Austria; Azerbaijan; Bahamas; Kingdom of Bahrain; 
Bangladesh; Barbados; Belarus; Belgium; Belize; Benin; Bhutan; Plurinational 
State of Bolivia; Bosnia and Herzegovina; Botswana; Brazil; Brunei Darussalam; 
Bulgaria; Burkina Faso; Burundi; Cabo Verde; Cambodia; Cameroon; Canada; 
Central African Republic; Chad; Chile; China; Colombia; Comoros; Congo; Costa 
Rica; Côte d 'Ivoire; Croatia; Cuba; Curaçao; Cyprus; Cz ech Republic; Democratic 
Republic of the Congo; Denmark; Djibouti; Dominica; Dominican Republic; 
Ecuador; Egypt; El Salvador; Equatorial Guinea; Estonia; Eswatini; Ethiopia; 
European Union; Fiji; Finland; France; Gabon; The Gambia; Georgia; Germany; 
Ghana;  Greece; Grenada; Guatemala; Guinea; Guinea -Bissau; Guyana; Haiti; 
Honduras; Hong Kong, China; Hungary; Iceland; India; Indonesia; Iran; Iraq; 
Ireland; Israel; Italy; Jamaica; Japan; Jordan; Kazakhstan; Kenya; Republic of 
Korea; the State of Kuwait; Kyrgyz  Republic; Lao People 's Democratic Republic; 
Latvia; Lebanese Republic; Lesotho; Liberia; Libya; Liechtenstein; Lithuania; 
Luxembourg; Macao, China; Madagascar; Malawi; Malaysia; Maldives; Mali; Malta; 
Mauritania; Mauritius; Mexico; Republic of Moldova; Mo ngolia; Montenegro; 
Morocco; Mozambique; Myanmar; Namibia; Nepal; Netherlands; New Zealand; 
Nicaragua; Niger; Nigeria; North Macedonia; Norway; Oman; Pakistan; Panama; 
Papua New Guinea; Paraguay; Peru; Philippines; Poland; Portugal; Qatar; 
Romania; Russian  Federation; Rwanda; Saint Kitts and Nevis; Saint Lucia; Saint 
Vincent and the Grenadines; Samoa; Sao Tomé and Principe; Kingdom of Saudi 
Arabia; Senegal; Serbia; Seychelles; Sierra Leone; Singapore; Slovak Republic; 
Slovenia; Solomon Islands; Somalia; Sou th Africa; South Sudan; Spain; Sri Lanka; 
Sudan; Suriname; Sweden; Switzerland; Syrian Arab Republic; The Separate 
Customs Territory of Taiwan, Penghu, Kinmen and Matsu; Tajikistan; Tanzania; 
Thailand; Timor -Leste; Togo; Tonga; Trinidad and Tobago; Tunisia ; Türkiye; 
Uganda; Ukraine; United Arab Emirates; United Kingdom; United States of 
America; Uruguay; Uzbekistan; Vanuatu; Bolivarian Republic of Venezuela; Viet 
Nam; Yemen; Zambia; Zimbabwe  
 
 
1 In English only.   
  IP/C/R/TC/WHO/3  
 
- 7 - Name of programme or project  WHO -WIPO -WTO COVID -19 Technical Ass istance Platform  
Brief description  Within the existing Trilateral collaboration framework between WHO, WIPO and 
WTO, the COVID -19 Technical Assistance Platform was created as a one -stop shop 
for the three organizations to make available their expertise in  public health, IP 
and trade matters in a coordinated and systematic manner to help Member States 
address the COVID -19 pandemic . 
Beneficiary institution or audience   
Technical cooperation provider(s)  WHO, WIPO, WTO  
Outputs or impact  The Platform also facilitates the provision of tripartite technical assistance on the 
pathways for accessing vaccines, medicines and technologies, including through 
coordination between members facing similar challenges to facilitate collective 
responses.  
Website for further information  https://www.who -wipo-wto-trilateral.org/  
Contact point for further information   
  
  IP/C/R/TC/WHO/3  
 
- 8 - Name of programme or project  WHO, WIPO, WTO Workshop on Innovation in, and Access to, COVID -19 
Technologies  
Date and end date  27 September 2021 - 27 September 2021  
Beneficiary Member(s) or observer(s)  Afghanistan; Albania; Algeria; Andorra; Angola; Antigua and Barbuda; Argentina; 
Armenia; Australia; Austria; Azerbaijan; Bahamas; Kingdom of Bahrain; 
Bangladesh; Barbados; Belarus; Belgium; Belize; Benin; Bhutan; Plurinational 
State of Bolivia; Bosnia and Herzegovina; Botswana; Brazil; Brunei Darussalam; 
Bulgaria; Burkina Faso; Burundi; Cabo Verde; Cambodia; Cameroon; Canada; 
Central African Republic; Chad; Chile; China; Colombia; Comoros; Congo; Costa 
Rica; Côte d 'Ivoire; Croatia; Cuba; Curaçao; Cyprus; Cz ech Republic; Democratic 
Republic of the Congo; Denmark; Djibouti; Dominica; Dominican Republic; 
Ecuador; Egypt; El Salvador; Equatorial Guinea; Estonia; Eswatini; Ethiopia; 
European Union; Fiji; Finland; France; Gabon; The Gambia; Georgia; Germany; 
Ghana;  Greece; Grenada; Guatemala; Guinea; Guinea -Bissau; Guyana; Haiti; 
Honduras; Hong Kong, China; Hungary; Iceland; India; Indonesia; Iran; Iraq; 
Ireland; Israel; Italy; Jamaica; Japan; Jordan; Kazakhstan; Kenya; Republic of 
Korea; the State of Kuwait; Kyrgyz  Republic; Lao People 's Democratic Republic; 
Latvia; Lebanese Republic; Lesotho; Liberia; Libya; Liechtenstein; Lithuania; 
Luxembourg; Macao, China; Madagascar; Malawi; Malaysia; Maldives; Mali; Malta; 
Mauritania; Mauritius; Mexico; Republic of Moldova; Mo ngolia; Montenegro; 
Morocco; Mozambique; Myanmar; Namibia; Nepal; Netherlands; New Zealand; 
Nicaragua; Niger; Nigeria; North Macedonia; Norway; Oman; Pakistan; Panama; 
Papua New Guinea; Paraguay; Peru; Philippines; Poland; Portugal; Qatar; 
Romania; Russian  Federation; Rwanda; Saint Kitts and Nevis; Saint Lucia; Saint 
Vincent and the Grenadines; Samoa; Sao Tomé and Principe; Kingdom of Saudi 
Arabia; Senegal; Serbia; Seychelles; Sierra Leone; Singapore; Slovak Republic; 
Slovenia; Solomon Islands; Somalia; Sou th Africa; South Sudan; Spain; Sri Lanka; 
Sudan; Suriname; Sweden; Switzerland; Syrian Arab Republic; The Separate 
Customs Territory of Taiwan, Penghu, Kinmen and Matsu; Tajikistan; Tanzania; 
Thailand; Timor -Leste; Togo; Tonga; Trinidad and Tobago; Tunisia ; Türkiye; 
Turkmenistan; Uganda; Ukraine; United Arab Emirates; United Kingdom; United 
States of America; Uruguay; Uzbekistan; Vanuatu; Bolivarian Republic of 
Venezuela; Viet Nam; Yemen; Zambia; Zimbabwe  
Brief description  The workshop, held virtually, con veyed information to enhance knowledge and 
understanding of how IP, know -how and technology transfer work in practice, not 
only vis -à-vis medical technologies but also for related products and services.  
Beneficiary institution or audience   
Technical coop eration provider(s)  WHO, WIPO, WTO  
Outputs or impact  The workshop was aimed at strengthening the capacity of policymakers and 
experts in member governments to address the pandemic.   
  IP/C/R/TC/WHO/3  
 
- 9 - Name of programme or project  WHO, WIPO, WTO Workshop on Innovation in, and Access to, COVID -19 
Technologies  
Website for further information  https://www.wipo.int/meetings/en/details.jsp?meeting_id=65948  
Contact point for further information   
 
Name of programme or project  WHO, WIPO and WTO workshop on access, use of information resources 
for COVID -19 response  
Date and end date  28 February 2022 - 28 February 2022  
Beneficiary Member(s) or observer(s)  Afghanistan; Albania; Angola; Antigua and Barbuda; Argentina; Armenia; 
Australia; Austria; Kingdom of Bahrain; Bangladesh; Barbados; Belgium; Belize; 
Benin; Plurinational State of Bolivia; Botswana; Brazil; Brunei Darussalam; 
Bulgaria; Burkina Faso; Burund i; Cabo Verde; Cambodia; Cameroon; Canada; 
Central African Republic; Chad; Chile; China; Colombia; Congo; Costa Rica; Côte 
d'Ivoire; Croatia; Cuba; Cyprus; Czech Republic; Democratic Republic of the 
Congo; Denmark; Djibouti; Dominica; Dominican Republic; E cuador; Egypt; El 
Salvador; Estonia; Eswatini; European Union; Fiji; Finland; France; Gabon; The 
Gambia; Georgia; Germany; Ghana; Greece; Grenada; Guatemala; Guinea; 
Guinea -Bissau; Guyana; Haiti; Honduras; Hong Kong, China; Hungary; Iceland; 
India; Indones ia; Ireland; Israel; Italy; Jamaica; Japan; Jordan; Kazakhstan; 
Kenya; Republic of Korea; the State of Kuwait; Kyrgyz Republic; Lao People 's 
Democratic Republic; Latvia; Lesotho; Liberia; Liechtenstein; Lithuania; 
Luxembourg; Macao, China; Madagascar; Mala wi; Malaysia; Maldives; Mali; Malta; 
Mauritania; Mauritius; Mexico; Republic of Moldova; Mongolia; Montenegro; 
Morocco; Mozambique; Myanmar; Namibia; Nepal; Netherlands; New Zealand; 
Nicaragua; Niger; Nigeria; North Macedonia; Norway; Oman; Pakistan; Panam a; 
Papua New Guinea; Paraguay; Peru; Philippines; Poland; Portugal; Qatar; 
Romania; Russian Federation; Rwanda; Saint Kitts and Nevis; Saint Lucia; Saint 
Vincent and the Grenadines; Samoa; Kingdom of Saudi Arabia; Senegal; 
Seychelles; Sierra Leone; Singapo re; Slovak Republic; Slovenia; Solomon Islands; 
South Africa; Spain; Sri Lanka; Suriname; Sweden; Switzerland; The Separate 
Customs Territory of Taiwan, Penghu, Kinmen and Matsu; Tajikistan; Tanzania; 
Thailand; Togo; Tonga; Trinidad and Tobago; Tunisia; Tü rkiye; Uganda; Ukraine; 
United Arab Emirates; United Kingdom; United States of America; Uruguay; 
Vanuatu; Bolivarian Republic of Venezuela; Viet Nam; Yemen; Zambia; Zimbabwe  
Brief description  The purpose of the workshop was to enhance understanding of the  characteristics, 
potential uses and limitations of particular information sources related to the 
pandemic.  
Beneficiary institution or audience    
  IP/C/R/TC/WHO/3  
 
- 10 - Name of programme or project  WHO, WIPO and WTO workshop on access, use of information resources 
for COVID -19 response  
Technical cooperation provider(s)  WHO, WIPO, WTO  
Outputs or impact   
Website for further information  https://www.wto.org/english/news_e/news22_e/trip_28feb22_e.htm  
Contact point for further information   
  
  IP/C/R/TC/WHO/3  
 
- 11 - Name of programme or project  License by Spanish National Research Council (CSIC) under auspices of 
WHO COVID -19 Technology Access Pool  
Date and end date  23 November 2021  
Beneficiary Member(s) or observer(s)  Afghanistan; Albania; Algeria; Andorra; Angola; Antigua and Barbuda; Argentina; 
Armenia; Australia; Austria; Azerbaijan; Bahamas; Kingdom of Bahrain; 
Bangladesh; Barbados; Belarus; Belgium; Belize; Benin; Bhutan; Plurinational 
State of Bolivia; Bosnia and Herzegovina; Botswana; Brazil; Brunei Darussalam; 
Bulgaria; Burkina Faso; Burundi; Cabo Verde; Cambodia; Cameroon; Canada; 
Central African Republic; Chad; Chile; China; Colombia; Comoros; Congo; Costa 
Rica; Côte d 'Ivoire; Croatia; Cuba; Curaçao; Cyprus; Cz ech Republic; Democratic 
Republic of the Congo; Denmark; Djibouti; Dominica; Dominican Republic; 
Ecuador; Egypt; El Salvador; Equatorial Guinea; Estonia; Eswatini; Ethiopia; Fiji; 
Finland; France; Gabon; The Gambia; Georgia; Germany; Ghana; Greece; 
Grenada ; Guatemala; Guinea; Guinea -Bissau; Guyana; Haiti; Honduras; Hong 
Kong, China; Hungary; Iceland; India; Indonesia; Iran; Iraq; Ireland; Israel; Italy; 
Jamaica; Japan; Jordan; Kazakhstan; Kenya; Republic of Korea; the State of 
Kuwait; Kyrgyz Republic; Lao P eople 's Democratic Republic; Latvia; Lebanese 
Republic; Lesotho; Liberia; Libya; Liechtenstein; Lithuania; Luxembourg; Macao, 
China; Madagascar; Malawi; Malaysia; Maldives; Mali; Malta; Mauritania; 
Mauritius; Mexico; Republic of Moldova; Mongolia; Monteneg ro; Morocco; 
Mozambique; Myanmar; Namibia; Nepal; Netherlands; New Zealand; Nicaragua; 
Niger; Nigeria; North Macedonia; Norway; Oman; Pakistan; Panama; Papua New 
Guinea; Paraguay; Peru; Philippines; Poland; Portugal; Qatar; Romania; Russian 
Federation; Rwa nda; Saint Kitts and Nevis; Saint Lucia; Saint Vincent and the 
Grenadines; Samoa; Sao Tomé and Principe; Kingdom of Saudi Arabia; Senegal; 
Serbia; Seychelles; Sierra Leone; Singapore; Slovak Republic; Slovenia; Solomon 
Islands; Somalia; South Africa; South  Sudan; Spain; Sri Lanka; Sudan; Suriname; 
Sweden; Switzerland; Syrian Arab Republic; The Separate Customs Territory of 
Taiwan, Penghu, Kinmen and Matsu; Tajikistan; Tanzania; Thailand; Timor -Leste; 
Togo; Tonga; Trinidad and Tobago; Tunisia; Türkiye; Turkm enistan; Uganda; 
Ukraine; United Arab Emirates; United Kingdom; United States of America; 
Uruguay; Uzbekistan; Vanuatu; Bolivarian Republic of Venezuela; Viet Nam; 
Yemen; Zambia; Zimbabwe  
Brief description  Under the auspices of C -TAP, the Medicines Patent  Pool (MPP) signed a worldwide 
license with the Spanish National Research Council (CSIC) for a COVID -19 
serological antibody diagnostic test.  The diagnostic test effectively checks for the 
presence of anti -SARS -CoV-2 antibodies developed either in response  to a 
COVID - 19 infection or to a vaccine. This license was the first transparent, global, 
non-exclusive license for a COVID -19 health tool, and the first test license signed 
by MPP and included in C -TAP. 
Beneficiary institution or audience  Medicines Pate nt Pool, manufacturers of COVID -19 health products, Biotech Africa   
  IP/C/R/TC/WHO/3  
 
- 12 - Name of programme or project  License by Spanish National Research Council (CSIC) under auspices of 
WHO COVID -19 Technology Access Pool  
Technical cooperation provider(s)  WHO 
Outputs or impact  The license will facilitate the rapid manufacture and commercialization of CSIC 's 
COVID -19 serological test worldwide. The agreemen t covers all related patents and 
the biological material necessary for manufacture of the test. CSIC will provide all 
know -how to prospective licensees as well as training. The license will be royalty -
free for low - and middle -income countries and will rema in valid until the date the 
last patent expires.  
Website for further information  https://www.who.int/initiatives/covid -19-technology -access -pool/csic -license  
Contact point for further information   
  
  IP/C/R/TC/WHO/3  
 
- 13 - Name of programme or project  Licenses by United States National Institutes of Health under the auspices 
of WHO COVID -19 Technology Access Pool  
Date and end date  12 May 2022  
Beneficiary Member(s) or observer(s)  Afghanistan; Albania; Angola; Antigua and Barbuda; Argentina; Armenia; 
Australia; Austria; Kingdom of Bahrain; Bangladesh; Barbados; Belgium; Belize; 
Benin; Plurinational State of Bolivia; Botswana; Brazil; Brunei Darussalam; 
Bulgaria; Burkina Faso; Burund i; Cabo Verde; Cambodia; Cameroon; Canada; 
Central African Republic; Chad; Chile; China; Colombia; Congo; Costa Rica; Côte 
d'Ivoire; Croatia; Cuba; Cyprus; Czech Republic; Democratic Republic of the 
Congo; Denmark; Djibouti; Dominica; Dominican Republic; E cuador; Egypt; El 
Salvador; Estonia; Eswatini; European Union; Fiji; Finland; France; Gabon; The 
Gambia; Georgia; Germany; Ghana; Greece; Grenada; Guatemala; Guinea; 
Guinea -Bissau; Guyana; Haiti; Honduras; Hong Kong, China; Hungary; Iceland; 
India; Indones ia; Ireland; Israel; Italy; Jamaica; Japan; Jordan; Kazakhstan; 
Kenya; Republic of Korea; the State of Kuwait; Kyrgyz Republic; Lao People 's 
Democratic Republic; Latvia; Lesotho; Liberia; Liechtenstein; Lithuania; 
Luxembourg; Macao, China; Madagascar; Mala wi; Malaysia; Maldives; Mali; Malta; 
Mauritania; Mauritius; Mexico; Republic of Moldova; Mongolia; Montenegro; 
Morocco; Mozambique; Myanmar; Namibia; Nepal; Netherlands; New Zealand; 
Nicaragua; Niger; Nigeria; North Macedonia; Norway; Oman; Pakistan; Panam a; 
Papua New Guinea; Paraguay; Peru; Philippines; Poland; Portugal; Qatar; 
Romania; Russian Federation; Rwanda; Saint Kitts and Nevis; Saint Lucia; Saint 
Vincent and the Grenadines; Samoa; Kingdom of Saudi Arabia; Senegal; 
Seychelles; Sierra Leone; Singapo re; Slovak Republic; Slovenia; Solomon Islands; 
South Africa; Spain; Sri Lanka; Suriname; Sweden; Switzerland; The Separate 
Customs Territory of Taiwan, Penghu, Kinmen and Matsu; Tajikistan; Tanzania; 
Thailand; Togo; Tonga; Trinidad and Tobago; Tunisia; Tü rkiye; Uganda; Ukraine; 
United Arab Emirates; United Kingdom; United States of America; Uruguay; 
Vanuatu; Bolivarian Republic of Venezuela; Viet Nam; Yemen; Zambia; Zimbabwe  
Brief description  Under the auspices of C -TAP, the Medicines Patent Pool signed t wo licensing 
agreements with the United States National Institutes of Health (NIH) for the 
development of 11 innovative therapeutics, early -stage vaccines and diagnostic 
tools for COVID -19. 
Beneficiary institution or audience  Medicines Patent Pool, manufacturers of COVID -19 health products  
Technical cooperation provider(s)  WHO 
Outputs or impact  This was the second worldwide, non -exclusive and transparent license for 
technologies included in C -TAP. 
Website for further information  https://www.who.int/news/item/12 -05-2022-who-and-mpp-announce -
agreement -with-nih-for-covid-19-health -technologies    
  IP/C/R/TC/WHO/3  
 
- 14 - Name of programme or project  Licenses by United States National Institutes of Health under the auspices 
of WHO COVID -19 Technology Access Pool  
Contact poin t for further information   
 
Name of programme or project  Webinar: Realizing equitable global access to COVID -19 health 
technologies. WHO C -TAP's progress, challenges and opportunities  
Date and end date  16 June 2022 - 16 June 2022  
Beneficiary Member(s) or observer(s)  Afghanistan; Albania; Angola; Antigua and Barbuda; Argentina; Armenia; 
Australia; Austria; Kingdom of Bahrain; Bangladesh; Barbados; Belgium; Belize; 
Benin; Plurinational State of Bolivia; Botswana; Brazil; Brunei Darussalam; 
Bulga ria; Burkina Faso; Burundi; Cabo Verde; Cambodia; Cameroon; Canada; 
Central African Republic; Chad; Chile; China; Colombia; Congo; Costa Rica; Côte 
d'Ivoire; Croatia; Cuba; Cyprus; Czech Republic; Democratic Republic of the 
Congo; Denmark; Djibouti; Domini ca; Dominican Republic; Ecuador; Egypt; El 
Salvador; Estonia; Eswatini; European Union; Fiji; Finland; France; Gabon; The 
Gambia; Georgia; Germany; Ghana; Greece; Grenada; Guatemala; Guinea; 
Guinea -Bissau; Guyana; Haiti; Honduras; Hong Kong, China; Hungary ; Iceland; 
India; Indonesia; Ireland; Israel; Italy; Jamaica; Japan; Jordan; Kazakhstan; 
Kenya; Republic of Korea; the State of Kuwait; Kyrgyz Republic; Lao People 's 
Democratic Republic; Latvia; Lesotho; Liberia; Liechtenstein; Lithuania; 
Luxembourg; Macao , China; Madagascar; Malawi; Malaysia; Maldives; Mali; Malta; 
Mauritania; Mauritius; Mexico; Republic of Moldova; Mongolia; Montenegro; 
Morocco; Mozambique; Myanmar; Namibia; Nepal; Netherlands; New Zealand; 
Nicaragua; Niger; Nigeria; North Macedonia; Norw ay; Oman; Pakistan; Panama; 
Papua New Guinea; Paraguay; Peru; Philippines; Poland; Portugal; Qatar; 
Romania; Russian Federation; Rwanda; Saint Kitts and Nevis; Saint Lucia; Saint 
Vincent and the Grenadines; Samoa; Kingdom of Saudi Arabia; Senegal; 
Seychell es; Sierra Leone; Singapore; Slovak Republic; Slovenia; Solomon Islands; 
South Africa; Spain; Sri Lanka; Suriname; Sweden; Switzerland; The Separate 
Customs Territory of Taiwan, Penghu, Kinmen and Matsu; Tajikistan; Tanzania; 
Thailand; Togo; Tonga; Trinida d and Tobago; Tunisia; Türkiye; Uganda; Ukraine; 
United Arab Emirates; United Kingdom; United States of America; Uruguay; 
Vanuatu; Bolivarian Republic of Venezuela; Viet Nam; Yemen; Zambia; Zimbabwe   
  IP/C/R/TC/WHO/3  
 
- 15 - Name of programme or project  Webinar: Realizing equitable global access to COVID -19 health 
technologies. WHO C -TAP's progress, challenges and opportunities  
Brief description  On its second -year anniversary, C -TAP organized a Panel Discussion Webinar to 
stimulate the debate on advancing C -TAP's ability to promote equitable access to 
COVID -19 health technologies, informed by two papers prepared by the C -TAP 
Secretariat. The first paper reviewed existing literature on technology transfer and 
affordable access in funding agreements in the context o f medical products to 
address pandemic diseases. The second paper provided a summary of responses 
by Member States to a WHO C -TAP incentive questionnaire. The second part of the 
paper included a review based on academic papers, conferences, and any other 
publicly available resource.  
Beneficiary institution or audience  Holders of knowledge, intellectual property or data to existing or new therapeutics, 
diagnostics and vaccines, governments, research and development funders, 
researchers, Patients and communi ties, inter -governmental, non -governmental 
and civil society organizations, other stakeholders . 
Technical cooperation provider(s)  WHO 
Outputs or impact   
Website for further information  https://www.who.int/news -room/events/detail/2022/06/16/default -
calendar/webinar --realizing -equitable -global -access -to-covid-19-health -
technologies. -who-c-tap-s-progress --challenges -and-opportunities  
Contact point for further information   
 
Name of programme or project  Selection of technology recipients from the mRNA vaccine technology 
transfer hub to produce mRNA vaccines  
Date and end date  18 February 2022  
Beneficiary Member(s) or observer(s)  Argentina; Bangladesh; Brazil; Egypt; India; Indonesia; Kenya; Nigeria; Pakistan; 
Senegal; Serbia; South Africa; Tunisia; Ukraine; Viet Nam  
Brief description  On 18 February 2022, WHO announced the first recipients of technology from the 
mRNA vaccine technology transfer hub to produce mRNA vaccines.  
Beneficiary institution or audience   
Technical cooperation provider(s)  WHO 
Outputs or impact  WHO and partners will work with the beneficiary countries to develop a roadmap 
for necessary training and support so that they can start producing vaccines on th e 
African continent.   
  IP/C/R/TC/WHO/3  
 
- 16 - Name of programme or project  Selection of technology recipients from the mRNA vaccine technology 
transfer hub to produce mRNA vaccines  
Website for further information  https://www.who.int/initiatives/the -mrna-vaccine -technology -transfer -
hub/recipients -of-mrna-technology -from-the-who-mrna-technology -transfer -hub  
Contact point for further information   
 
Name of programme or project  Establishment of a global bio -manufacturing training hub in Republic of 
Korea  
Date and end date  23 February 2022  
Beneficiary Member(s) or observer(s)   
Brief description  WHO led the establishment of a global bio -manufacturing training hub in the 
Republic of Korea to serve all low - and middle -income countries wishing to produce 
biologicals, such as vaccines, insulin, monoclonal antibodies and cancer 
treatments.  
Beneficiary institution or audience   
Technical cooperation provider(s)  WHO 
Outputs or impact  The facility will provide technical and hands -on training on operat ional and good 
manufacturing practice requirements and is set to complement the trainings 
delivered by the mRNA vaccine technology transfer hub in South Africa.  
Website for further information  https://www.who.int/news/item/23 -02-2022-moving -forward -on-goal-to-boost -
local-pharmaceutical -production -who-establishes -global-biomanufacturing -
training -hub-in-republic -of-korea   
Contact point for further information   
 
 
 
__________